

**OTHER TRANSACTION AGREEMENT (OTA)**

**OTHER TRANSACTION FOR ADVANCED RESEARCH (OTAR)**

**BETWEEN**

**Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591-6717**

**AND**

**THE UNITED STATES OF AMERICA  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE  
200 C Street, S.W.  
WASHINGTON, DC 20515**

**CONCERNING**

**Novel Antibodies against Influenza Virus, Emerging, re-Emerging, and pre-Emerging pathogens**

**Modification No. 0005**

**Date: February 12, 2020**

**PR No.: OS 206444 \$18,693,213; OS 233799 \$19,274,081; OS234612 \$278,812; OS 253326 \$5,751,859**

**Total Amount of the Agreement: \$54,997,457 (Unchanged)**

**Total Estimated Government Funding of the Agreement: \$43,997,965 (Unchanged)**

**Total Estimated Recipient Funding of the Agreement: \$10,999,492 (Unchanged)**

**Funds Obligated: \$43,997,965 (Unchanged)**

**Period of Performance: September 30, 2017 through June 30, 2022 (Unchanged)**

**Authority: Section 319L(c) (4) (B) and/or 319L(c) (4) (D) of the Pandemic and All-Hazards Preparedness Act, P.L. 109-417**

**Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 1994027**

**(b)(4) (CLIN 0001)**

**Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 199TWLN**

**(b)(4) (CLIN 0001)**

**Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 1994047**

**(b)(4) (CLIN 0001).**

**Line of Accounting and Appropriation: Object Class 25106, Appropriation Yr: 2017, CAN: 1994044**

**(b)(4) (CLIN 0001).**

**Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 1994027**

**(b)(4) (CLIN 0002)**

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2017, CAN: 199TWLN  
(b)(4) CLIN 0003)

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2019, CAN: 199TWRY  
(b)(4) CLIN 0001 and (b)(4) CLIN 0002)

Line of Accounting and Appropriation: Object Class: 25106, Appropriation Yr: 2019, CAN: 1992019  
(b)(4) (CLIN 0001)

Line of Accounting and Appropriation: Object Class: 25106; Appropriation Yr: 2020, CAN: 1992020  
(b)(4) CLIN 0001 and (b)(4) CLIN 0002)

**PURPOSE:** The purpose of this modification is to realign CLIN 0003 (Option 2) moving (b)(4)  
(b)(4) Attachment 6 (Requisition Table) is added which reflects the  
associated requisitions and their Flu or Host activities.

Beginning with the effective date of this modification, the Government and Other Transaction Agreement holder mutually agree as follows:

1. Attached is the document which supports the addition of Attachment 6 – Requisition Table.

All other terms and conditions remain the same.

FOR THE UNITED STATES OF AMERICA  
OFFICE OF ACQUISITION MANAGEMENT,  
CONTRACTS & GRANTS SECRETARY  
FOR PREPAREDNESS AND RESPONSE

Wendell  
Conyers -S

Digitally signed by Wendell  
Conyers -S  
Date: 2020.02.14 11:06:08  
-05'00'

02/14/2020

(Signature)

(Date)

Wendell Conyers  
Supervisory Contract Specialist, Branch Chief  
Other Transaction Agreement Officer

FOR Regeneron Pharmaceuticals, Inc.

(b)(6)  
2/12/2020  
(Signature) (Date)  
Robert E. Landry,  
Executive Vice President, Finance and Chief Financial Officer, Regeneron Pharmaceuticals, Inc.

END OF MODIFICATION No. 0005 TO HHSO100201700020C